2015 American Transplant Congress
Everolimus-Based Immunosuppression Is Associated With a Reduced Risk of New-Onset Malignancies After Liver Transplantation
Background and aim: The inhibitor of the mammalian target of rapamycin (mTOR) everolimus (EVR) has shown anti-proliferative effects in experimental and clinical models. We investigated…2015 American Transplant Congress
Clinical Outcomes of Kidney Transplan Recipients After Sirolimus Or Everolimus Conversion. Experience in a Single Center
Transplant Unit, Fundación Valle del Lili, Cali, Colombia.
Introduction. The use of m_TOR inhibitors sirolimus (SRL) and everolimus (EVL), in kidney transplant recipients (KTR) is an alternative immunosuppressive therapy to reduce or withdrawal…
- « Previous Page
- 1
- …
- 18
- 19
- 20